Management of hyperbilirubinaemia in pancreatic cancer patients

被引：9

作者：

Alvarez, R. ^{[1
]}

Carrato, A. ^{[2
]}

Adeva, J. ^{[3
]}

Ales, I. ^{[4
]}

Prados, S. ^{[5
]}

Valladares, M. ^{[6
]}

Macarulla, T. ^{[7
]}

Munoz, A. ^{[8
]}

Hidalgo, M. ^{[9
]}

机构：

[1] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain

[2] Alcala Univ, Ramon y Cajal Univ Hosp, CIBERONC, IRYCIS,Dept Med Oncol, Madrid, Spain

[3] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[4] Hosp Reg Univ Malaga, Dept Med Oncol, Malaga, Spain

[5] Hosp Univ HM Sanchinarro, Dept Gastroenterol, Madrid, Spain

[6] Hosp Univ Virgen Rocia Sevilla, Dept Med Oncol, Seville, Spain

[7] Hosp Valle De Hebron, Dept Med Oncol, Barcelona, Spain

[8] Hosp Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[9] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2018年 / 94卷

关键词：

Hyperbilirubinemia; Pancreatic adenocarcinoma; Management; PREOPERATIVE BILIARY DRAINAGE; NAB-PACLITAXEL; HEPATIC-DYSFUNCTION; PHASE-I; FOLINIC ACID; SOLID TUMORS; GEMCITABINE; OXALIPLATIN; PHARMACOLOGY; IRINOTECAN;

D O I：

10.1016/j.ejca.2018.01.078

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Development of hyperbilirubinaemia is common in patients with advanced pancreatic adenocarcinoma, both at diagnosis as well throughout disease evolution. For this reason, hyperbilirubinaemia determines chemotherapy treatment selection, and therefore it should be considered one of the most relevant conditions. There is very little evidence for the use of chemotherapy in this setting. This article summarises the main causes of hyperbilirubinaemia, how to treat them as well as their differential diagnosis. The current clinical evidence of the available drugs as well as the recommendations of use different combinations in the context of hyperbilirubinaemia are also reviewed. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：26 / 36

页数：11

共 57 条

[1]

AAPRO MS, 1998, ANTI-CANCER DRUG, V9, P515

[2] Plastic vs. Self-Expandable Metal Stents for Palliation in Malignant Biliary Obstruction: A Series of Meta-Analyses [J].

Almadi, Majid A. ;

Barkun, Alan ;

Martel, Myriam .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (02) :260-273

[3]

[Anonymous], J NATL CANC I

[4] 5 YEARS CLINICAL EXPERIENCE WITH 5-FLUOROURACIL [J].

ANSFIELD, FJ ;

CURRERI, AR ;

SCHROEDER, JM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1962, 181 (04) :295-+

[5] Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction [J].

Baur, Martina ;

Drescher, Anne ;

Gneist, Margit ;

Dittrich, Christian ;

Jaehde, Ulrich .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) :97-104

[6] nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study [J].

Biakhov, Mikhail Y. ;

Kononova, Galina V. ;

Iglesias, Jose ;

Desai, Neil ;

Bhar, Paul ;

Schmid, Anita N. ;

Loibl, Sibylle .

EXPERT OPINION ON DRUG SAFETY, 2010, 9 (04) :515-523

[7] Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction [J].

Briasoulis, Evangelos ;

Karavasilis, Vasilis ;

Tzamakou, Eleftheria ;

Piperidou, Christina ;

Soulti, Kali ;

Pavlidis, Nicholas .

ANTI-CANCER DRUGS, 2006, 17 (10) :1219-1222

[8] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[9] A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs [J].

Carrato A. ;

Falcone A. ;

Ducreux M. ;

Valle J.W. ;

Parnaby A. ;

Djazouli K. ;

Alnwick-Allu K. ;

Hutchings A. ;

Palaska C. ;

Parthenaki I. .

Journal of Gastrointestinal Cancer, 2015, 46 (3) :201-211

[10] Pharmacokinetics and Pharmacodynamics of nab-Paclitaxel in Patients With Solid Tumors: Disposition Kinetics and Pharmacology Distinct From Solvent-Based Paclitaxel [J].

Chen, Nianhang ;

Li, Yan ;

Ye, Ying ;

Palmisano, Maria ;

Chopra, Rajesh ;

Zhou, Simon .

JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (10) :1097-1107

← 1 2 3 4 5 6 →